Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Mangrove Partners Reports 17% Stake in Asta Funding Inc (ASFI); Plans Tender Offer for 3.0 Mln Shares

Nathaniel August‘s Mangrove Partners has reported a 17.4% stake in Asta Funding, Inc. (NASDAQ:ASFI) via a 13D filing with the US Securities and Exchange Commission. The position contains around 2.10 million shares and is higher than the 1.46 million-share holding that Mangrove disclosed in its last 13F filing. In addition, the investor stated that it plans to launch a tender offer to purchase up to 3.0 million shares of Asta Funding at a price of $9.00 per unit. With this tender offer, Mangrove would increase its position in Asta to over 42% of the outstanding stock.

Among the funds we track, two other shareholders of Asta Funding are Brian Gaines’ Springhouse Capital Management and Jim Simons’ Renaissance Technologies, which own 648,683 shares and 126,300 shares, respectively.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
THE MANGROVE PARTNERS FUND 2,102,427 2,102,427 2,102,427 17.4%
MANGROVE PARTNERS FUND (CAYMAN), LTD 2,102,427 2,102,427 2,102,427 17.4%
MANGROVE PARTNERS 2,102,427 2,102,427 2,102,427 17.4%
MANGROVE CAPITAL 2,102,427 2,102,427 2,102,427 17.4%
MPF INVESTCO 4 2,102,427 2,102,427 2,102,427 0%

Page 1 of 17 SEC Filing

Washington, D.C. 20549
(Rule 13d-101)
§ 240.13d-2(a)
(Amendment No. 1)1
Asta Funding, Inc.
(Name of Issuer)
Common Stock, $0.01 par value
(Title of Class of Securities)
(CUSIP Number)
Park Avenue Tower
65 East 55th Street
New York, New York 10022
(212) 451-2300
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 15, 2016
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box x.
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.
1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Asta Funding Inc (NASDAQ:ASFI)
Trade (NASDAQ:ASFI) Now!

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.